These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 28801865)

  • 1. Faecal lactoferrin and calprotectin in patients with Clostridium difficile infection: a case-control study.
    Barbut F; Gouot C; Lapidus N; Suzon L; Syed-Zaidi R; Lalande V; Eckert C
    Eur J Clin Microbiol Infect Dis; 2017 Dec; 36(12):2423-2430. PubMed ID: 28801865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calprotectin and lactoferrin faecal levels in patients with Clostridium difficile infection (CDI): a prospective cohort study.
    Swale A; Miyajima F; Roberts P; Hall A; Little M; Beadsworth MB; Beeching NJ; Kolamunnage-Dona R; Parry CM; Pirmohamed M
    PLoS One; 2014; 9(8):e106118. PubMed ID: 25170963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation between fecal calprotectin levels, disease severity and the hypervirulent ribotype 027 strain in patients with Clostridium difficile infection.
    Peretz A; Tkhawkho L; Pastukh N; Brodsky D; Halevi CN; Nitzan O
    BMC Infect Dis; 2016 Jun; 16():309. PubMed ID: 27334992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of Clostridium difficile infection: a suggested laboratory diagnostic algorithm.
    Wren MW; Kinson R; Sivapalan M; Shemko M; Shetty NR
    Br J Biomed Sci; 2009; 66(4):175-9. PubMed ID: 20095124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fecal calprotectin concentrations in cancer patients with Clostridium difficile infection.
    He T; Kaplan SE; Gomez LA; Lu X; Ramanathan LV; Kamboj M; Tang YW
    Eur J Clin Microbiol Infect Dis; 2018 Dec; 37(12):2341-2346. PubMed ID: 30242543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Occurrence of Clostridium difficile ribotype 027 in hospitals of Silesia, Poland.
    Aptekorz M; Szczegielniak A; Wiechuła B; Harmanus C; Kuijper E; Martirosian G
    Anaerobe; 2017 Jun; 45():106-113. PubMed ID: 28216085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated fecal calprotectin associates with adverse outcomes from Clostridium difficile infection in older adults.
    Rao K; Santhosh K; Mogle JA; Higgins PD; Young VB
    Infect Dis (Lond); 2016 Sep; 48(9):663-9. PubMed ID: 27206404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ribotype 027 Clostridium difficile infections with measurable stool toxin have increased lactoferrin and are associated with a higher mortality.
    Boone JH; Archbald-Pannone LR; Wickham KN; Carman RJ; Guerrant RL; Franck CT; Lyerly DM
    Eur J Clin Microbiol Infect Dis; 2014 Jun; 33(6):1045-51. PubMed ID: 24449345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is there any value in measuring faecal calprotectin in Clostridium difficile positive faecal samples?
    Whitehead SJ; Shipman KE; Cooper M; Ford C; Gama R
    J Med Microbiol; 2014 Apr; 63(Pt 4):590-593. PubMed ID: 24464697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid faecal tests for detecting disease activity in colonic inflammatory bowel disease.
    Puolanne AM; Kolho KL; Alfthan H; Ristimäki A; Mustonen H; Färkkilä M
    Eur J Clin Invest; 2016 Oct; 46(10):825-32. PubMed ID: 27438629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated lactoferrin is associated with moderate to severe Clostridium difficile disease, stool toxin, and 027 infection.
    Boone JH; DiPersio JR; Tan MJ; Salstrom SJ; Wickham KN; Carman RJ; Totty HR; Albert RE; Lyerly DM
    Eur J Clin Microbiol Infect Dis; 2013 Dec; 32(12):1517-23. PubMed ID: 23771554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive value of fecal calprotectin and lactoferrin levels for negative outcomes in Clostridioides difficile infection.
    Ágreda Fernández M; Origüen J; Rodriguez-Goncer I; San Juan R; López-Medrano F; Parra P; Ruiz-Merlo T; Redondo N; Orellana MÁ; Aguado JM; Fernández-Ruiz M
    Eur J Clin Microbiol Infect Dis; 2024 Feb; 43(2):313-324. PubMed ID: 38072880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential of lactoferrin to prevent antibiotic-induced Clostridium difficile infection.
    Chilton CH; Crowther GS; Śpiewak K; Brindell M; Singh G; Wilcox MH; Monaghan TM
    J Antimicrob Chemother; 2016 Apr; 71(4):975-85. PubMed ID: 26759363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Presence of lactoferrin in faeces as the indicator of Clostridium difficile in pediatric patients].
    Dąbrowskal S; Demkow U; Podsiadły E
    Med Dosw Mikrobiol; 2015; 67(1):1-8. PubMed ID: 26084069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Age-related faecal calprotectin, lactoferrin and tumour M2-PK concentrations in healthy volunteers.
    Joshi S; Lewis SJ; Creanor S; Ayling RM
    Ann Clin Biochem; 2010 May; 47(Pt 3):259-63. PubMed ID: 19740914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fecal calprotectin in management of Clostridium difficile infection: a longitudinal study.
    Gallo A; Vallone C; Sabatelli L; Ventura G; Covino M; Cammarota G; Gasbarrini A; Landolfi R; Montalto M
    Scand J Gastroenterol; 2018 May; 53(5):567-572. PubMed ID: 29065739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fecal Calprotectin Level Reflects the Severity of Clostridium difficile Infection.
    Kim J; Kim H; Oh HJ; Kim HS; Hwang YJ; Yong D; Jeong SH; Lee K
    Ann Lab Med; 2017 Jan; 37(1):53-57. PubMed ID: 27834066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Organism burden, toxin concentration, and lactoferrin concentration do not distinguish between clinically significant and nonsignificant diarrhea in patients with Clostridium difficile.
    Anikst VE; Gaur RL; Schroeder LF; Banaei N
    Diagn Microbiol Infect Dis; 2016 Apr; 84(4):343-6. PubMed ID: 26778484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year.
    Guidi L; Marzo M; Andrisani G; Felice C; Pugliese D; Mocci G; Nardone O; De Vitis I; Papa A; Rapaccini G; Forni F; Armuzzi A
    Dig Liver Dis; 2014 Nov; 46(11):974-9. PubMed ID: 25096964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low sensitivity of fecal toxin A/B enzyme immunoassay for diagnosis of Clostridium difficile infection in immunocompromised patients.
    Erb S; Frei R; Strandén AM; Dangel M; Tschudin-Sutter S; Widmer AF
    Clin Microbiol Infect; 2015 Nov; 21(11):998.e9-998.e15. PubMed ID: 26232535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.